Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Neumora Therapeutics Begins Phase 1 Clinical Trial Of NMRA-861, A Selective M4 Positive Allosteric Modulator For Schizophrenia

Author: Benzinga Newsdesk | July 09, 2025 06:08am

NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile
No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits

Posted In: NMRA